BioSpace News Archive

Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of their latest demand management solution for a medical device company.

Parks Associates will examine the market for IoT health solutions and current trends in the connected health market during “Connected Health: Serving Consumers at Home,” the pre-show workshop for Connected Health Summit on August 27.

The world largest online healthcare platform, Ping An Good Doctor (01833.HK), has seen its share price rise sharply recently, closing at HK $48.35 on 23 August, up 6.73%.

Philip C. Brittain, DO with Vibrant Life is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED).

Jennifer Trinidad, with Body Renaissance is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED).

Charles Lively MD is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED).

Phyllis Okereke, MD, FAARFM with Shioma Anti-Aging is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided an update on its on-going clinical trial of levosimendan

Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the publication of two articles in Science that significantly advance the understanding of the structure and function of SARM1, a protein that is a critical regulator of cellular degeneration, and provide further support for the centrality of the NAD+-cleavage pathway in mediating cellular degeneration across multiple species.

The global bronchiectasis drugs market size is poised to grow by USD 117.57 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of close to 5% during the forecast period.